These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3523516)

  • 1. Current cellular assays for measuring clinical drug metabolizing capacity--impact of new molecular biologic techniques.
    Kouri RE; McLemore T; Jaiswal AK; Nebert DW
    Prog Clin Biol Res; 1986; 214():453-69. PubMed ID: 3523516
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial pharmacogenetics.
    Wilke RA; Reif DM; Moore JH
    Nat Rev Drug Discov; 2005 Nov; 4(11):911-8. PubMed ID: 16264434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic factors in drug metabolism.
    Belle DJ; Singh H
    Am Fam Physician; 2008 Jun; 77(11):1553-60. PubMed ID: 18581835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug metabolism by the cytochrome p-450 enzyme. Variability of polymorphisms and exogenous carriers].
    Kreutzkamp B
    Med Monatsschr Pharm; 2006 Feb; 29(2):48-50. PubMed ID: 16506587
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacogenetics and its importance in the clinical].
    Lares-Asseff I; Trujillo-Jiménez F
    Gac Med Mex; 2001; 137(3):227-36. PubMed ID: 11432091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of knowledge on drug metabolism for the safe use of drugs in humans.
    Oesch F
    Drug Metab Rev; 2009; 41(3):298-300. PubMed ID: 19601716
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.
    Johnson AD; Wang D; Sadee W
    Pharmacol Ther; 2005 Apr; 106(1):19-38. PubMed ID: 15781120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug essentials. The cytochrome P450 microenzyme system and targeted therapies: Minimizing drug interactions.
    Wilkes GM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl Nurse Ed):33, 52-6. PubMed ID: 19856586
    [No Abstract]   [Full Text] [Related]  

  • 12. Genes and the response to drugs.
    Caraco Y
    N Engl J Med; 2004 Dec; 351(27):2867-9. PubMed ID: 15625340
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic polymorphisms in drug-metabolizing enzymes and drug targets.
    Hiratsuka M; Mizugaki M
    Mol Genet Metab; 2001 Aug; 73(4):298-305. PubMed ID: 11509011
    [No Abstract]   [Full Text] [Related]  

  • 14. [Genetic polymorphism of the hepatic metabolism of drugs].
    Larrey D; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1985; 9(6-7):522-31. PubMed ID: 3926587
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular map of the human genome as a basis for the study of ethnic differences in reactions to xenobiotics.
    Grzeschik KH
    Prog Clin Biol Res; 1986; 214():479-88. PubMed ID: 3460098
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
    Andersson T; Flockhart DA; Goldstein DB; Huang SM; Kroetz DL; Milos PM; Ratain MJ; Thummel K
    Clin Pharmacol Ther; 2005 Dec; 78(6):559-81. PubMed ID: 16338273
    [No Abstract]   [Full Text] [Related]  

  • 18. How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing.
    Roberts RL; Begg EJ; Joyce PR; Kennedy MA
    N Z Med J; 2002 Mar; 115(1150):137-40. PubMed ID: 12013308
    [No Abstract]   [Full Text] [Related]  

  • 19. Population genetic structure of variable drug response.
    Wilson JF; Weale ME; Smith AC; Gratrix F; Fletcher B; Thomas MG; Bradman N; Goldstein DB
    Nat Genet; 2001 Nov; 29(3):265-9. PubMed ID: 11685208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In case of risks and side effects: ask your genes, too].
    Möritz A
    Med Monatsschr Pharm; 2007 May; 30(5):179-83. PubMed ID: 17526394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.